



3 September 2014

ASX ANNOUNCEMENT

ImpediMed (ASX:IPD)

L-Dex[®] granted reimbursement status for all cancer related lymphoedema

HIGHLIGHTS

- Transformational event for ImpediMed, reimbursement status for use of L-Dex across all relevant cancer types
- Expands L-Dex addressable market opportunity to over US\$ 350 million per annum

ImpediMed (ASX:IPD) is pleased to announce today that the American Medical Association (AMA) has released the CPT[®] Category I Code descriptor for bioimpedance spectroscopy - code 93702 - which describes the Company's L-Dex procedure for the assessment of lymphoedema. This new, unique code encompasses all cancer related lymphoedema.

The clinician descriptor for CPT Category I code 93702 for L-Dex is "Bioimpedance-derived spectroscopy for extracellular fluid analysis". This will be used for lymphoedema assessment using the L-Dex device. This has been published in the AMA CPT 2015 data file.

CPT Category I codes are the most sought after government reimbursement codes available in the US. These codes enable all Medicare eligible patients to be reimbursed by the US Government for services provided.

This is a transformational event for ImpediMed. The receipt of this Category I Code descriptor means that reimbursement for L-Dex is not limited to specifically breast cancer patients, but rather significantly expands the market opportunity for L-Dex to all cancer patients who are at risk of developing lymphoedema. This new addressable market is approximately 940,000 patients each year in the US alone and estimated to be in excess of US\$ 350 million per annum.

"This is a real game-changer for ImpediMed" said Richard Carreon, CEO of ImpediMed. "Securing a unique CPT I Code is a significant achievement, and one that very few Australian companies have managed. We are now increasing our focus on the wider oncology market to positively impact a far greater number of patients."

The reimbursement rates for all new codes will be determined by the Centers for Medicare and Medicaid Services (CMS). These rates will be published in November 2014, and are effective on 1st January 2015.

Investor Conference Call

Investors are invited to join a conference call hosted by Richard Carreon, CEO on **Wednesday 3rd September at 11.00am AEST.**

To access the call please use the dial in details below:

Conference ID: 404 916

Conference Call Toll-Free Access Numbers

Australia	1800 558 698		
New Zealand	0800 453 055	Japan	0053 116 1281
China	4001 200 659	Singapore	800 101 2785
Canada	1855 8811 339	United Kingdom	0800 051 8245
Hong Kong	800 966 806	United States	1855 8811 339

For all other locations please dial: +61 2 9007 3187

ENDS

For further information contact:
Richard Carreon, ImpediMed CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Kyahn Williamson, Buchan
Investor and Media Relations
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au